2025 Chemotherapy-Induced Nausea and Vomiting (CINV) Industry Trends Report: Long-Term Outlook Through 2034

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size By 2025?
The market size for chemotherapy-induced nausea and vomiting (CINV) has been rapidly expanding in recent years. It is projected to increase from $2.92 billion in 2024 to $3.15 billion in 2025, displaying a compound annual growth rate (CAGR) of 7.9%. The upward trend during the historical period can be explained by increased utilization of chemotherapy, advancements in antiemetic medications, enhanced clinical guidelines, and patient advocacy.

How Big Is the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Expected to Grow by 2029?
The market for chemotherapy-induced nausea and vomiting (CINV) is anticipated to experience robust expansion in the upcoming years. It's predicted to reach $4.2 billion by 2029, expanding at a compound annual growth rate (CAGR) of 7.5%. Factors contributing to growth during the forecasted period include personalized medical treatments, improvements in antiemetic drugs, telehealth and remote observation, as well as health equality initiatives. The forecast period is expected to be influenced by major trends such as combination antiemetic treatments, supportive care services, digital health instruments, and survivorship care.

View the full report here:
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

Which Key Market Drivers Powering Chemotherapy-Induced Nausea and Vomiting (CINV) Market Expansion and Growth?
The escalation in cancer's prevalence is anticipated to fuel the progression of the chemotherapy-induced nausea and vomiting (CINV) market. Cancer occurs when cells in the body multiply uncontrollably and infiltrate other parts of the body. As the incidence of cancer rises, there is an escalating urgency to formulate more potent and focused anti-emetic therapies to ease CINV, an upsetting aftermath of chemotherapy. This intensified attention on CINV management has led to breakthroughs in grasping its underlying processes and formulating new treatments. For instance, according to data from the American Cancer Society (ACS), a volunteer health organization centered on ending cancer based in the US, it's forecasted that there will be roughly 1.9 million new cancer cases (about 5,370 cases daily) and 609,820 cancer fatalities (around 1,670 deaths daily) in the US in 2023. Thus, the rising prevalence of cancer will be a significant driving factor for the chemotherapy-induced nausea and vomiting (CINV) market. Benign regulatory initiatives are expected to bolster the expansion of the chemotherapy-induced nausea and vomiting (CINV) market. Regulatory initiatives involve measures taken by regulatory authorities to create, implement, or enforce rules. These initiatives can be utilized to enhance the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) by developing and implementing guidelines for its prevention and management. For example, according to the US's Food and Drug Administration, CDER (Center for Drug Evaluation and Research), a division of the U.S. Food and Drug Administration, sanctioned 55 new drugs for chemotherapy-induced nausea and vomiting (CINV) in 2023. Hence, the surge in favorable regulatory initiatives is propelling the chemotherapy-induced nausea and vomiting (CINV) market growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
Leading organizations in the chemotherapy-induced nausea and vomiting (CINV) market are focusing on the development of new products like fixed intravenous antiemetic to secure a competitive edge. Fixed intravenous antiemetic is a medication given in a set dose through an IV to counteract or cure nausea and vomiting commonly linked with chemotherapy or post-surgery scenarios. For example, in January 2023, Glenmark Pharmaceuticals Limited, an Indian pharmaceutical, generics, and over-the-counter (OTC) products manufacturer, became the pioneer to launch AKYNZEO I.V. in India, a novel fixed intravenous antiemetic combo designed to stay CINV at bay. This product brings together netupitant and palonosetron, addressing both the immediate and postponed stages of nausea and vomiting. It allows for a one-time dosage, augments complete response rates, and provides a better quality of life for cancer patients. The product is notably advantageous for patients undergoing highly emetogenic chemotherapy, as per clinical trials.

What Are the Emerging Segments in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
The chemotherapy-induced nausea and vomiting (CINV) market covered in this report is segmented -

1) By Form: Injectables, Oral, Transdermal Patches
2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Class
3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)
4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores
5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications

Subsegments:
1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections
2) By Oral: Tablets, Capsules, Liquid Formulations
3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13031&type=smp

Who Are the Global Leaders in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

Which are the Top Profitable Regional Markets for the Chemotherapy-Induced Nausea and Vomiting (CINV) Industry?
North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13031

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.